Turnstone Biologics Corp

Turnstone Biologics Corp(TSBX)財務資料

$0.355

+0.005 (+1.43%)收盤時

TSBX 獲利能力與利潤率

Evaluating the bottom line, Turnstone Biologics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -126.71%, provide a clear picture of how effectively TSBX converts its operational activities into shareholder value.

TSBX 同業比較

In the context of the broader market, TSBX competes directly with industry leaders such as ADVB and TRAW. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TSBX's gross margin of N/A stands against ADVB's N/A and TRAW's N/A. Such benchmarking helps identify whether Turnstone Biologics Corp is trading at a premium or discount relative to its financial performance.

Financials

FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY:
-83.41%
-3.66M
Operating Profit
FY2025Q2
YoY:
-74.23%
-5.49M
Net Income after Tax
FY2025Q2
YoY:
-73.91%
-0.24
EPS - Diluted
FY2025Q2
YoY:
-73.15%
-4.30M
Free Cash Flow
FY2023Q4
YoY:
0.00%
100.00
Gross Profit Margin - %
FY2023Q4
YoY:
+235.69%
-349.12
FCF Margin - %
FY2023Q4
YoY:
+579.63%
-285.92
Net Margin - %

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始